Institution
University of Ostrava
Education•Ostrava, Czechia•
About: University of Ostrava is a education organization based out in Ostrava, Czechia. It is known for research contribution in the topics: Fuzzy logic & Fuzzy number. The organization has 1755 authors who have published 4060 publications receiving 57185 citations. The organization is also known as: Ostravská univerzita v Ostravě.
Topics: Fuzzy logic, Fuzzy number, Fuzzy set, Fuzzy set operations, Population
Papers published on a yearly basis
Papers
More filters
University of Texas MD Anderson Cancer Center1, University of California, Davis2, City of Hope National Medical Center3, University of Chicago4, Harvard University5, Monash University6, University of Ulm7, University of Paris8, Université catholique de Louvain9, McMaster University10, University of Barcelona11, Peking Union Medical College12, University of Zagreb13, University of Ostrava14, University of Helsinki15, University of Debrecen16, University of Genoa17, Seoul National University18, Sungkyunkwan University19, China Medical University (Taiwan)20, Ondokuz Mayıs University21, Genentech22, AbbVie23, University of Pennsylvania24
TL;DR: In previously untreated patients with confirmed AML who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received zsitidine alone.
Abstract: Background Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising effica...
1,097 citations
TL;DR: Some fuzzy linear programming methods and techniques from a practical point of view are reviewed and some newly developed ideas and techniques in fuzzy mathematical programming are briey reviewed.
731 citations
National and Kapodistrian University of Athens1, University of Nantes2, University of Turin3, Royal Prince Alfred Hospital4, University of Ostrava5, Heidelberg University6, University of Eastern Piedmont7, Box Hill Hospital8, University of Western Ontario9, Monash University10, University of Texas MD Anderson Cancer Center11, Onyx Pharmaceuticals12, National University of Singapore13
TL;DR: The primary endpoint was progression-free survival in the intention-to-treat population and carfilzomib with dexamethasone could be considered in patients with relapsed or refractory multiple myeloma.
Abstract: Summary Background Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Methods In this randomised, phase 3, open-label, multicentre study, patients with relapsed or refractory multiple myeloma who had one to three previous treatments were randomly assigned (1:1) using a blocked randomisation scheme (block size of four) to receive carfilzomib with dexamethasone (carfilzomib group) or bortezomib with dexamethasone (bortezomib group). Randomisation was stratified by previous proteasome inhibitor therapy, previous lines of treatment, International Staging System stage, and planned route of bortezomib administration if randomly assigned to bortezomib with dexamethasone. Patients received treatment until progression with carfilzomib (20 mg/m 2 on days 1 and 2 of cycle 1; 56 mg/m 2 thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or intravenous infusion) or bortezomib (1·3 mg/m 2 ; intravenous bolus or subcutaneous injection) and dexamethasone (20 mg oral or intravenous infusion). The primary endpoint was progression-free survival in the intention-to-treat population. All participants who received at least one dose of study drug were included in the safety analyses. The study is ongoing but not enrolling participants; results for the interim analysis of the primary endpoint are presented. The trial is registered at ClinicalTrials.gov, number NCT01568866. Findings Between June 20, 2012, and June 30, 2014, 929 patients were randomly assigned (464 to the carfilzomib group; 465 to the bortezomib group). Median follow-up was 11·9 months (IQR 9·3–16·1) in the carfilzomib group and 11·1 months (8·2–14·3) in the bortezomib group. Median progression-free survival was 18·7 months (95% CI 15·6–not estimable) in the carfilzomib group versus 9·4 months (8·4–10·4) in the bortezomib group at a preplanned interim analysis (hazard ratio [HR] 0·53 [95% CI 0·44–0·65]; p vs 45 [10%] of 456 patients in the bortezomib group), hypertension (41 [9%] vs 12 [3%]), thrombocytopenia (39 [8%] vs 43 [9%]), and pneumonia (32 [7%] vs 36 [8%]). Interpretation For patients with relapsed or refractory multiple myeloma, carfilzomib with dexamethasone could be considered in cases in which bortezomib with dexamethasone is a potential treatment option. Funding Onyx Pharmaceuticals, Inc., an Amgen subsidiary.
686 citations
TL;DR: These Clinical Practice Guidelines are endorsed by the Japanese Society of Medical Oncology (JSMO) incidence and epidemiology Multiple myeloma accounts for 1% ofall cancers and ∼10% of all haematological malignancies.
658 citations
International Agency for Research on Cancer1, University of Bristol2, University Hospitals Bristol NHS Foundation Trust3, Vanderbilt University Medical Center4, University of Kentucky5, University of Copenhagen6, Lund University7, Technische Universität München8, Fred Hutchinson Cancer Research Center9, Harvard University10, Dartmouth College11, University of Liverpool12, Umeå University13, National Institute of Occupational Health14, New Generation University College15, Radboud University Nijmegen16, BC Cancer Agency17, Washington State University18, University of Hawaii19, Ontario Institute for Cancer Research20, University of Southern California21, Technion – Israel Institute of Technology22, University of Salzburg23, Curie Institute24, Nofer Institute of Occupational Medicine25, University of Ostrava26, Charles University in Prague27, Nanjing Medical University28, University of Oviedo29, University of Sheffield30, University of Texas MD Anderson Cancer Center31, University of Pittsburgh32, Lunenfeld-Tanenbaum Research Institute33
TL;DR: The results are consistent with a causal role of fasting insulin and low-density lipoprotein cholesterol in lung cancer etiology, as well as for BMI in squamous cell and small cell carcinoma, and the latter relation may be mediated by a previously unrecognized effect of obesity on smoking behavior.
Abstract: Background: Assessing the relationship between lung cancer and metabolic conditions is challenging because of the confounding effect of tobacco. Mendelian randomization (MR), or the use of genetic ...
653 citations
Authors
Showing all 1774 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Ajith Abraham | 86 | 1113 | 31834 |
| Joseph Hamill | 72 | 360 | 16477 |
| Vladimir Janout | 60 | 248 | 14378 |
| Radko Mesiar | 59 | 642 | 15010 |
| Colin Brownlee | 59 | 188 | 16682 |
| Roman Hájek | 56 | 625 | 16135 |
| Kamil Kuca | 55 | 1029 | 16708 |
| Vilém Novák | 38 | 216 | 5131 |
| Vyacheslav Yurchenko | 37 | 132 | 4514 |
| Győző Garab | 36 | 153 | 4952 |
| Irina Perfilieva | 34 | 246 | 4675 |
| Vaclav Snasel | 33 | 673 | 6216 |
| Marek Eliáš | 32 | 97 | 7712 |
| Steriani Elavsky | 32 | 81 | 8986 |
| Radim Belohlavek | 31 | 183 | 4200 |